英夫利昔单抗治疗儿童克罗恩病的概况
Profile of infliximab in the treatment of pediatric Crohn's disease.
作者信息
Kierkus Jaroslaw, Szymanska Edyta, Oracz Grzegorz, Wiernicka Anna, Dadalski Maciej
机构信息
Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics.
Department of Pediatrics, Nutrition and Metabolic Disorders, The Children's Memorial Health Institute, Warsaw, Poland.
出版信息
Pediatric Health Med Ther. 2015 Jun 11;6:79-85. doi: 10.2147/PHMT.S64943. eCollection 2015.
Abstract
In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn's disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the growing popularity of infliximab in the management of Crohn's disease, we review the profile of the agent in the treatment of this disease in a pediatric setting.
摘要
近年来，一种针对肿瘤坏死因子-α的单克隆抗体新型生物疗法彻底改变了克罗恩病的治疗方式。首个生物制剂英夫利昔单抗已被证明能显著改善临床和内镜检查结果。鉴于英夫利昔单抗在克罗恩病治疗中的日益普及，我们综述了该制剂在儿科环境中治疗这种疾病的概况。
相似文献
1
Profile of infliximab in the treatment of pediatric Crohn's disease.英夫利昔单抗治疗儿童克罗恩病的概况
Pediatric Health Med Ther. 2015 Jun 11;6:79-85. doi: 10.2147/PHMT.S64943. eCollection 2015.
2
Transcending conventional therapies: the role of biologic and other novel therapies.超越传统疗法：生物制剂及其他新型疗法的作用
Inflamm Bowel Dis. 2001 May;7 Suppl 1:S9-16. doi: 10.1002/ibd.3780070504.
3
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.英夫利昔单抗和其他抗肿瘤坏死因子 α 治疗药物治疗炎症性肠病。
BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000.
4
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.用于维持克罗恩病缓解的肿瘤坏死因子-α抗体。
Cochrane Database Syst Rev. 2008 Jan 23(1):CD006893. doi: 10.1002/14651858.CD006893.
5
[Anti-TNF therapy in treatment of luminal Crohn's disease].[抗TNF治疗在腔内型克罗恩病治疗中的应用]
Acta Med Croatica. 2013 Apr;67(2):179-89.
6
Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.英夫利昔单抗在儿童早期而非晚期克罗恩病中的反应持续时间延长。
Am J Gastroenterol. 2000 Nov;95(11):3189-94. doi: 10.1111/j.1572-0241.2000.03263.x.
7
Ineffectiveness of infliximab therapy in severe infantile Crohn's disease.英夫利昔单抗治疗严重婴儿期克罗恩病无效。
J Crohns Colitis. 2010 Feb;4(1):106-9. doi: 10.1016/j.crohns.2009.08.004. Epub 2009 Sep 9.
8
Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group.澳大利亚早期使用英夫利昔单抗（一种抗肿瘤坏死因子-α的嵌合抗体）治疗克罗恩病的经验：类固醇节省免疫抑制疗法能否增强其疗效？英夫利昔单抗用户组
Intern Med J. 2001 Apr;31(3):146-50. doi: 10.1046/j.1445-5994.2001.00039.x.
9
Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.英夫利昔单抗：关于其在克罗恩病和类风湿性关节炎中应用的最新综述
BioDrugs. 2002;16(2):111-48. doi: 10.2165/00063030-200216020-00005.
10
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.英夫利昔单抗抗肿瘤坏死因子抗体用于克罗恩病的内镜及组织学愈合：一项欧洲多中心试验
Gastroenterology. 1999 May;116(5):1029-34. doi: 10.1016/s0016-5085(99)70005-3.
引用本文的文献
1
Inflammatory Bowel Disease in Children: Current Diagnosis and Treatment Strategies.儿童炎症性肠病：当前的诊断与治疗策略
Cureus. 2025 Feb 3;17(2):e78462. doi: 10.7759/cureus.78462. eCollection 2025 Feb.
2
Assessment of systemic genetic damage in pediatric inflammatory bowel disease.评估小儿炎症性肠病的系统性遗传损伤。
Environ Mol Mutagen. 2020 Nov;61(9):901-909. doi: 10.1002/em.22403. Epub 2020 Aug 22.
本文引用的文献
1
Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series.英夫利昔单抗生物类似药CT-P13用于炎症性肠病患者的临床经验：病例系列
Dig Dis Sci. 2015 Apr;60(4):951-6. doi: 10.1007/s10620-014-3392-z. Epub 2014 Oct 18.
2
Early anti-TNF treatment in pediatric Crohn's disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patients.儿童克罗恩病的早期抗肿瘤坏死因子治疗。基于人群的新诊断患者队列中临床结局的预测因素。
Scand J Gastroenterol. 2014 Dec;49(12):1425-31. doi: 10.3109/00365521.2014.966316. Epub 2014 Oct 13.
3
Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID.抗 TNF 治疗的克罗恩病患者肠外瘘的长期结局：GETAID 的队列研究。
Am J Gastroenterol. 2014 Sep;109(9):1443-9. doi: 10.1038/ajg.2014.183. Epub 2014 Aug 5.
4
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.欧洲克罗恩病和结肠炎组织/欧洲儿科胃肠病、肝病和营养学会关于儿童克罗恩病药物治疗的共识指南。
J Crohns Colitis. 2014 Oct;8(10):1179-207. doi: 10.1016/j.crohns.2014.04.005. Epub 2014 Jun 6.
5
Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.与硫唑嘌呤相比，抗肿瘤坏死因子药物可减少克罗恩病患者的皮质类固醇使用量。
Curr Med Res Opin. 2014 Sep;30(9):1821-6. doi: 10.1185/03007995.2014.928273. Epub 2014 Jun 2.
6
Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease.英夫利昔单抗可维持持久疗效并促进腔外型小儿克罗恩病患儿的追赶生长。
Inflamm Bowel Dis. 2014 Jul;20(7):1177-86. doi: 10.1097/MIB.0000000000000083.
7
A review of CT-P13: an infliximab biosimilar.CT-P13综述：英夫利昔单抗生物类似药
BioDrugs. 2014 Jun;28(3):313-21. doi: 10.1007/s40259-014-0094-1.
8
Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.儿童克罗恩病抗 TNF 治疗后的黏膜愈合：单中心长期经验。
Eur J Gastroenterol Hepatol. 2014 Apr;26(4):458-65. doi: 10.1097/MEG.0000000000000045.
9
Predictors of response to Infliximab in children with luminal Crohn's disease.腔内型克罗恩病患儿对英夫利昔单抗反应的预测因素
J Crohns Colitis. 2014 Aug;8(8):739-46. doi: 10.1016/j.crohns.2013.12.017. Epub 2014 Jan 18.
10
Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease.克罗恩病患儿接受英夫利昔单抗治疗一年期间，IMPACT-III与儿童克罗恩病活动指数的自回归交叉滞后模型
J Crohns Colitis. 2014 Aug;8(8):747-55. doi: 10.1016/j.crohns.2013.12.020. Epub 2014 Jan 14.
Zotero 插件